Jefferies is providing some comments on Pfizer's PFE JAK inhibitor, tofacitinib.
“Oral targeted disease modifying Rheumatoid Arthritis (RA) treatments were the hot topic at this year's European League Against Rheumatism (EULAR) annual meeting, last week (May 25-28),” Jefferies writes.
“Pfizer's JAK inhibitor tofacitinib is the closest to market. Further clarity and reassurance of the drug's safety was gained from the data presented at the meeting. We expect peak sales of $6.5bn for tofacitinib.”
Pfizer closed Friday at $20.93.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in